Vicapsys Life Sciences, Inc. (VICP) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $21.0M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerVicapsys Life Sciences, Inc. (VICP) trades at $0.65. Vicapsys Life Sciences, Inc. is a biotechnology company focused on developing and commercializing VICAPSYN for transplantation therapies and VYBRIN for surgical adhesion prevention and wound healing. Market cap: $21.0M, Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for VICP: VICP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
Vicapsys Life Sciences, Inc. (VICP) Healthcare & Pipeline Overview
Vicapsys Life Sciences, Inc., a biotechnology firm, is dedicated to the advancement of VICAPSYN for transplantation and VYBRIN for surgical applications. With a focus on innovative therapies, the company aims to address critical needs in transplantation and post-surgical care, operating in the competitive biotechnology landscape.
What Is the Investment Thesis for VICP?
Vicapsys Life Sciences, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on VICAPSYN and VYBRIN addresses significant unmet needs in transplantation and surgical recovery, respectively. Key value drivers include successful clinical trials and regulatory approvals for its products. However, the company's small size and limited resources pose significant challenges. The current market capitalization of $21.0M reflects the early stage of development and inherent risks. A negative P/E ratio of -81.12 indicates that the company is not currently profitable. The company's beta of -4.13 suggests an inverse correlation with the market, which may be misleading given its developmental stage. Successful advancement of VICAPSYN and VYBRIN through clinical trials and subsequent commercialization could drive substantial value creation. However, potential setbacks in clinical development, regulatory hurdles, and competition pose significant risks.
Based on FMP financials and quantitative analysis
VICP Key Highlights
Market capitalization of $21.0M reflects early-stage development and inherent risks.
- Negative P/E ratio of -81.12 indicates the company is not currently profitable.
- The company is focused on developing VICAPSYN for transplantation therapies and VYBRIN for surgical applications.
- The company has a small team of 2 employees.
- Beta of -4.13 suggests an inverse correlation with the market, which may be misleading given its developmental stage.
Who Are VICP's Competitors?
VICP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ACHFF Arch Biopartners Inc. | $0.57 | -0.35% | $38.8M | — |
| CLTEF Calliditas Therapeutics Ab | $0.18 | 0.00% | $10.5M | — |
| HBPCF Helix BioPharma Corp. | $0.77 | 0.00% | $58.8M | — |
| INNMF Amplia Therapeutics Limited | $0.08 | -5.88% | $41.1M | — |
| OTLC Oncotelic Therapeutics, Inc. | $0.02 | -6.10% | $8.87M | — |
| ICCC ImmuCell Corporation | $9.75 | +1.56% | $88.2M | 79 5-pillar |
| RLYB Rallybio Corporation | $17.08 | +1.91% | $90.6M | 83 5-pillar |
| ALPX Alopexx, Inc. | $9.96 | 0.00% | $119M | 65 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VICP's Key Strengths?
Proprietary technology platform with potential for multiple applications.
- Focus on unmet medical needs in transplantation and surgical recovery.
- Potential for first-mover advantage in specific therapeutic areas.
What Are VICP's Weaknesses?
Small size and limited financial resources.
- Early stage of development with significant clinical and regulatory risks.
- Dependence on successful development and commercialization of VICAPSYN and VYBRIN.
What Could Drive VICP Stock Higher?
Clinical trial results for VICAPSYN in transplantation therapies.
- Pre-clinical data release for VYBRIN in surgical adhesion prevention.
- Announcement of strategic partnerships or licensing agreements.
- Continued research and development efforts to advance product pipeline.
What Are the Key Risks for VICP?
Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or regulatory setbacks for VICAPSYN and VYBRIN.
- Competition from larger, more established biotechnology and pharmaceutical companies.
- Intellectual property challenges and patent disputes.
- Limited financial resources and dependence on external funding.
- Risks associated with operating in the highly regulated biotechnology industry.
What Are the Growth Opportunities for VICP?
- Advancement of VICAPSYN in Transplantation Therapies: The market for transplantation therapies is substantial, driven by the increasing prevalence of organ failure and the need for improved outcomes. Successful clinical trials and regulatory approval for VICAPSYN could lead to significant revenue generation. The company's proprietary technology offers a potential competitive advantage in this market. Timeline: Ongoing clinical trials with potential for regulatory submission within the next 3-5 years.
- Development and Commercialization of VYBRIN for Surgical Adhesion Prevention: Post-surgical adhesions are a common complication following abdominal surgery, leading to significant morbidity and healthcare costs. VYBRIN's potential to prevent these adhesions represents a significant market opportunity. Successful development and commercialization could generate substantial revenue. Timeline: Pre-clinical development ongoing, with potential for clinical trials within the next 2-3 years.
- Expansion of VYBRIN into Wound Healing Applications: Diabetic ulcers represent a significant unmet medical need, with limited effective treatment options. VYBRIN's potential to promote wound healing offers a promising avenue for growth. Successful development and commercialization could generate significant revenue. Timeline: Pre-clinical development ongoing, with potential for clinical trials within the next 2-3 years.
- Strategic Partnerships and Licensing Agreements: Vicapsys can leverage strategic partnerships with larger pharmaceutical or biotechnology companies to accelerate the development and commercialization of its products. Licensing agreements can provide upfront payments, milestone payments, and royalties, providing a significant source of revenue. Timeline: Ongoing efforts to establish partnerships and licensing agreements.
- Expansion into New Therapeutic Areas: Vicapsys can leverage its core technology platform to expand into new therapeutic areas beyond transplantation and surgical recovery. This could involve developing new products or applications for its existing technologies. Timeline: Long-term strategy, with potential for expansion within the next 5-7 years.
What Are VICP's Competitive Advantages?
- Proprietary technology platform based on VICAPSYN and VYBRIN.
- Intellectual property protection through patents and trade secrets.
- Focus on niche markets with unmet medical needs.
- Potential for first-mover advantage in specific therapeutic areas.
What Does VICP Do?
Vicapsys Life Sciences, Inc., originally incorporated in 1997 as Phage Therapeutics International, Inc., underwent a name change in September 2017 to reflect its evolved focus. Based in Cumming, Georgia, the company is dedicated to the development and commercialization of its proprietary product, VICAPSYN, which is designed for use in transplantation therapies and related stem-cell applications. Recognizing the significant challenges in transplantation, Vicapsys aims to improve outcomes and reduce complications associated with these procedures. In addition to VICAPSYN, Vicapsys is also developing VYBRIN, a product based on CXCL12. VYBRIN is being developed for multiple applications, including the prevention of post-surgical adhesions following abdominal surgery, coating of implantable medical devices to minimize fibrosis, and promoting wound healing, particularly in diabetic ulcers. The company's focus on these areas reflects a commitment to addressing unmet medical needs and improving patient outcomes through innovative biotechnological solutions. With a small team of 2 employees, Vicapsys Life Sciences, Inc. is focused on advancing its product pipeline and seeking strategic partnerships to support its commercialization efforts.
What Products and Services Does VICP Offer?
- Develop VICAPSYN for transplantation therapies and related stem-cell applications.
- Develop VYBRIN for prevention of post-surgical adhesions in abdominal surgery.
- Develop VYBRIN for coating of implantable medical devices to eliminate fibrosis.
- Develop VYBRIN for wound healing, focusing on diabetic ulcers.
- Conduct research and development activities to advance its product pipeline.
- Seek regulatory approvals for its products from relevant authorities.
- Explore strategic partnerships and licensing agreements to support commercialization.
How Does VICP Make Money?
- Develop and commercialize proprietary products for transplantation and surgical applications.
- Generate revenue through product sales and licensing agreements.
- Invest in research and development to expand its product pipeline.
- Seek strategic partnerships to support commercialization efforts.
What Industry Does VICP Operate In?
Vicapsys Life Sciences, Inc. operates within the biotechnology industry, a sector characterized by high innovation, significant regulatory hurdles, and intense competition. Vicapsys' focus on transplantation and surgical recovery places it within a niche segment of this broader market. The company faces competition from larger, more established biotechnology and pharmaceutical companies, as well as smaller, specialized firms. Success in this environment requires strong intellectual property, successful clinical trials, and effective commercialization strategies.
Who Are VICP's Key Customers?
- Hospitals and transplant centers that perform transplantation procedures.
- Surgeons who perform abdominal surgeries.
- Patients who require transplantation or surgical procedures.
- Medical device manufacturers seeking to coat implantable devices.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
Company Profile
Vicapsys Life Sciences, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Suwanee, US. The company is led by CEO Federico Pier. VICP has traded publicly since 1998.
How Vicapsys Life Sciences, Inc. Is Valued
Vicapsys Life Sciences, Inc. carries a market capitalization of $21.0M, placing it in the micro-cap category.
Key Financial Metrics
Return on equity for Vicapsys Life Sciences, Inc. stands at 8.6%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.04 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -1.2%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Vicapsys Life Sciences, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Insider Activity
9 transactions · 0 purchases, 3 sales, 6 other transactions · 5 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
VICP Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Proprietary technology platform with potential for multiple applications.
- Focus on unmet medical needs in transplantation and surgical recovery.
- Potential for first-mover advantage in specific therapeutic areas.
- Upcoming: Clinical trial results for VICAPSYN in transplantation therapies.
Bear Case
- Small size and limited financial resources.
- Early stage of development with significant clinical and regulatory risks.
- Dependence on successful development and commercialization of VICAPSYN and VYBRIN.
- Potential: Clinical trial failures or regulatory setbacks for VICAPSYN and VYBRIN.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
VICP Latest News
No recent news available for VICP.
VICP Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for VICP.
Price Targets
Wall Street price target analysis for VICP.
VICP MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for VICP; grades run from A+ (80-100) to F (below 30).
Leadership: Federico Pier
CEO
Federico Pier serves as the CEO of Vicapsys Life Sciences, Inc. His background includes experience in managing small teams and guiding early-stage biotechnology companies. However, his leadership is focused on advancing the company's product pipeline and securing strategic partnerships.
Track Record: Under Federico Pier's leadership, Vicapsys Life Sciences, Inc. has focused on the development of VICAPSYN and VYBRIN. Specific milestones and achievements under his leadership are not detailed in the provided data. His focus is on navigating the challenges of a small biotechnology company and advancing its products through the development process.
VICP OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, characterized by limited or no financial disclosure and minimal listing requirements. Companies in this tier often face challenges in raising capital and attracting investor interest due to the lack of transparency and regulatory oversight. Investing in OTC Other stocks carries significant risks compared to stocks listed on major exchanges like the NYSE or NASDAQ, which have stricter listing standards and reporting requirements. These exchanges require companies to meet minimum financial thresholds, maintain corporate governance standards, and provide regular financial disclosures to investors.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in VICP.
- Low liquidity can result in significant price volatility and difficulty in executing trades.
- The OTC Other tier carries a higher risk of fraud and manipulation compared to major exchanges.
- The company may face challenges in raising capital due to its OTC listing.
- Lack of regulatory oversight increases the risk of investing in VICP.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's intellectual property and competitive landscape.
- Evaluate the company's business model and revenue potential.
- Review the company's capitalization table and ownership structure.
- Consult with a qualified financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- The company's focus on developing innovative therapies for transplantation and surgical recovery.
- The company's intellectual property portfolio, including patents and trade secrets.
- The company's efforts to seek strategic partnerships and licensing agreements.
- The company's history of operating since 1997.
VICP Healthcare Stock FAQ
Is VICP a good stock to buy?
Stock Expert AI does not rate VICP buy, sell or hold. Vicapsys Life Sciences, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the VICP stock price today?
The last price recorded on this page for Vicapsys Life Sciences, Inc. (VICP) is $0.65, as of the Oct 2, 2026 trading session. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for VICP?
The main risks for Vicapsys Life Sciences, Inc. include the inherent challenges of developing and commercializing new therapies in the biotechnology industry. Competition from larger, more established companies poses a threat.
What are the key factors to evaluate for VICP?
Evaluate VICP on fundamentals, analyst consensus, and risk factors. Key value drivers include successful clinical trials and regulatory approvals for its products. Not financial advice.
How frequently does VICP data refresh on this page?
VICP's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven VICP's recent stock price performance?
Vicapsys Life Sciences, Inc. (VICP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary technology platform with potential for multiple applications. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider VICP overvalued or undervalued right now?
Vicapsys Life Sciences, Inc. (VICP) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research VICP before investing?
Before investing in Vicapsys Life Sciences, Inc. (VICP), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on limited data sources.
- OTC market investments carry significant risks.